Onco-Innovations Income Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023
Revenue	0.11	0.07	-	-
Revenue Growth	69.06%	-	-	-
Gross Profit	0.11	0.07	-	-
Selling, General & Admin	9.61	4.48	0.06	0
Research & Development	1.27	0.24	-	-
Other Operating Expenses	0	0.01	-	-
Total Operating Expenses	10.89	4.73	0.06	0
Operating Income	-10.78	-4.67	-0.06	-0
Total Non-Operating Income (Expense)	-	-2.89	-	-
Pretax Income	-10.78	-7.56	-0.06	-0
Net Income	-10.78	-7.56	-0.06	-0
Net Income to Common	-10.78	-7.56	-0.06	-0
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	55	41	3	0
Shares Outstanding (Diluted)	55	41	3	0
Shares Change	35.96%	1071.62%	348214200.00%	-
EPS (Basic)	-0.19	-0.18	-0.04	-234.00
EPS (Diluted)	-0.19	-0.18	-0.04	-234.00
EPS Growth	-	-	-	-
Free Cash Flow	-5.27	-3.87	-0.01	-0
Free Cash Flow Growth	-	-	-	-
Free Cash Flow Per Share	-0.09	-0.09	-0.00	-233.00
Gross Margin	100.00%	100.00%	-	-
Operating Margin	-9763.39%	-7151.57%	-	-
Profit Margin	-9763.39%	-11580.60%	-	-
FCF Margin	-4772.97%	-5925.34%	-	-
EBITDA	-10.78	-4.67	-0.06	-0
EBIT	-10.78	-4.67	-0.06	-0
EBIT Margin	-9763.39%	-7151.57%	-	-